Trial Profile
A phase III, randomized, multicenter, double-blind, parallel-group, placebo-controlled safety and efficacy study of Adderall XR [SLI-381] [extended release] with an open label extension, in the treatment of adolescents aged 13-17 with ADHD [attention-deficit hyperactivity disorder]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jun 2021
Price :
$35
*
At a glance
- Drugs Mixed amfetamine salts (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Shire
- 18 Aug 2007 New trial record.